Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT06682351
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06682351
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06682351. Randomized; no masking; primary purpose treatment. Start 2024-11 (anticipated); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
- Condition
- Prediabetes / Type 2 Diabetes
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- GLP-1A
- Intervention (Dietary supplement)
- MED
- Lead sponsor
- Stanford University
Record details
- Record id
cardio:ct-nct06682351- Content hash
7b38901d37ec90e3c9bb00d7a0b6ce68fcdbfc5568960ed448a6d47378db92c1